The challenge Novo Nordisk faces in China underscores a bigger shift in the Chinese biopharma industry.
Illustration by Sam Ward
Novo Nordisk is feeling good about China. In March, the pharmaceutical company behind the blockbuster diabetes-turned-weight loss drug Ozempic held its “Capital Markets Day” presentations and held a breakout session devoted to its strong showing and trajectory in China. As Maziar Mike Doustdar, head of international operations, put it “all of our competitors combined are not able to cover what we do.”
He had good reason to be cocky: Novo Nordisk’s sales of Ozempic in China doubl
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
The former Biden official and China scholar makes the case for the previous administration's approach and discusses why Beijing is content to watch the U.S. now dismantle its sources of strength
Navigate China's Business Landscape with Confidence.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
